clinical trial · NCT04594369
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis BronchiectasisBrensocatib 10 mgBrensocatib 25 mgPlacebo
brief summary
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
started
Dec 1, 2020
primary completion
Oct 28, 2024
completion
Oct 28, 2024
last updated
Dec 16, 2025
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol